Nanoform, an innovative nanoparticle medicine enabling company, signed an agreement to manufacture GMP nanoformed material for an international company headquartered in Europe. This follows the Letter of Intent (LOI), signed between the parties in June 2021, to nanoform and develop, manufacture, and commercialize an improved version of a currently marketed drug.   The GMP agreement is for early clinical development. The final contract terms for commercialization will be negotiated as the proje...